The effect of Islamic Fasting in Ramadan on Osteoporosis

Document Type : Review Article


1 Department of Biology, Faculty of Science, University of Zabol, Zabol, Islamic Republic of Iran

2 Institute of Social Security & Welfare Applied Science Higher Education Tehran Province, University of Applied Science and Technology, Tehran, Iran.

3 Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran


Osteoporosis is considered as one of the most common diseases that women face after their menopause and is caused by both genetic and environmental factors.  Dipeptidyl peptidase 4 (DPP-4) gene is one of the important genetic factors contributing in osteoporosis which has a direct and very important relationship with fasting. Fasting is one of the alternatives proved to reduce the DPP-4 level and activate the Dipeptidyl peptidase 4 inhibitors and so, prevent osteoporosis. On the other hand, the circadian rhythm has a direct relationship with osteoporosis. This has been found by the biochemical markers, indicating that fasting at certain hours of the day, especially during those hours of the day which are recommended as part of the Muslim tradition, is very effective in reducing the effects of osteoporosis.


  1. Bahijri SM, Ajabnoor GM, Borai A, Al-Aama JY, Chrousos GP. Effect of Ramadan fasting in Saudi Arabia on serum bone profile and immunoglobulins. Ther Adv Endocrinol Metab. 2015; 6(5):223–32.
  2. Rouhani MH, Azadbakht L. Is Ramadan fasting related to health outcomes? A review on the related evidence. J Res Med Sci. 2014; 19(10):987–92.
  3. Azizi F. Islamic fasting and health. Ann Nutr Metab. 2010; 56(4):273–82.
  4. Wan Md Adnan WA, Zaharan NL, Wong MH, Lim SK. The Effects of intermittent fasting during the month of Ramadan in chronic haemodialysis patients in a tropical climate country. PLoS One. 2014; 9(12):e114262.
  5. Pontiroli AE, Pajetta E, Calderara A, Alberetto M, Pozza G, Manganelli V, et al. Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget’s disease of bones: a pilot study. J Endocrinol Invest. 1991; 14(1):47–51.
  6. Kasperk C, Georgescu C, Nawroth P. Diabetes mellitus and bone metabolism. Exp Clin Endocrinol Diabetes. 2017; 125(4):213–7.
  7. Vallejo R. Current management of osteoporotic spine fractures. Perspectives. 2003; 2:1-6.
  8. Einollahi B, Shahyad S, Lotfiazar A. Re: clinical and biochemical parameters of hemodialysis patients before and during the islamic Ramadan month. Iran J Kidney Dis. 2017; 11(2):168.
  9. Rahman M, Rashid M, Basher S, Sultana S, Nomani MZ. Improved serum HDL cholesterol profile among Bangladeshi male students during Ramadan fasting. East Mediterr Health J. 2004; 10(1–2):131–7.
  10. Benjamin I, Griggs RC, Wing EJ, Fitz JG. Andreoli and Carpenter’s Cecil Essentials of Medicine E-Book. 9th ed. New York: Elsevier Health Sciences; 2016.
  11. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev. 2008; 29(4):403–40.
  12. Maughan RJ, Leiper JB, Bartagi Z, Zrifi R, Zerguini Y, Dvorak J. Effect of Ramadan fasting on some biochemical and haematological parameters in Tunisian youth soccer players undertaking their usual training and competition schedule. J Sports Sci. 2008; 26(Suppl 3):S39-46.
  13. Dewanti L, Watanabe C, Sulistiawati, Ohtsuka R. Unexpected changes in blood pressure and hematological parameters among fasting and nonfasting workers during Ramadan in Indonesia. Eur J Clin Nutr. 2006; 60(7):877–81.
  14. Orozco P. Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women. Eur J Epidemiol. 2004; 19(12):1105–12.
  15. Salehi M, Aulinger BA, D’Alessio DA. Targeting β-Cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev. 2008; 29(3):367–79.
  16. Ramadan J, Telahoun G, Al-Zaid NS, Barac-Nieto M. Responses to exercise, fluid, and energy balances during Ramadan in sedentary and active males. Nutrition. 1999; 15(10):735–9.
  17. Attarzadeh Hosseini SR, Hejazi K. The effects of ramadan fasting and physical activity on blood hematological-biochemical parameters. Iran J Basic Med Sci. 2013; 16(7):845–9.
  18. Norouzy A, Salehi M, Philippou E, Arabi H, Shiva F, Mehrnoosh S, et al. Effect of fasting in Ramadan on body composition and nutritional intake: a prospective study. J Hum Nutr Diet. 2013; 26(Suppl 1):97–104.
  19. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264–9.
  20. Baerts L, Glorie L, Maho W, Eelen A, Verhulst A, D’Haese P, et al. Potential impact of sitagliptin on collagen-derived dipeptides in diabetic osteoporosis. Pharmacol Res. 2015; 100:336–40.
  21. Zheng T, Gao Y, Baskota A, Chen T, Ran X, Tian H. Increased plasma DPP4 activity is predictive of prediabetes and type 2 diabetes onset in chinese over a four-year period: result from the China National Diabetes and Metabolic Disorders Study. J Clin Endocrinol Metab. 2014; 99(11):E2330–4.
  22. Kagal U, Angadi NB, Matule SM. Effect of dipeptidyl peptidase 4 inhibitors on acute and subacute models of inflammation in male Wistar rats: an experimental study. Int J Appl Basic Med Res. 2017; 7(1):26-31.
  23. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011; 34(11):2474–6.
  24. Zheng T, Yang L, Liu Y, Liu H, Yu J, Zhang X, et al. Plasma DPP4 activities are associated with osteoporosis in postmenopausal women with normal glucose tolerance. J Clin Endocrinol Metab. 2015; 100(10):3862–70.
  25. Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res. 2004; 36(11-12):867–76.
  26. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007; 23(4):919–31.
  27. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006; 49(11):2564–71.
  28. Born M, Elmadfa I, Schmahl FW. Effects of periodical fluid and food withdrawal. An inquiry conducted during the lenten month Ramadan on foreign workers (author’s transl). MMW Munch Med Wochenschr. 1979; 121(47):1569–72.
  29. Ahmed MH, Abdu TA. Diabetes and Ramadan: an update on use of glycemic therapies during fasting. Ann Saudi Med. 2011; 31(4):402–6.
  30. Schlemmer A, Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur J Endocrinol. 1999; 140(4):332–7.
  31. Kocian J, Brodan V. Simultaneous correction of ca deficiency and acidosis in fasting obese patients as a prevention of bone demineralisation. Ann Nutr Metab. 1979; 23(5):391–8.
  32. Ceccarelli E, Guarino EG, Merlotti D, Patti A, Gennari L, Nuti R, et al. Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism. Front Endocrinol (Lausanne). 2013; 4:73.